IJCRR - 6(5), March, 2014
TOPICAL VERSUS CONTINUOUS BETAMETHASONE DIPROBIONATE PHONOPHORESIS IN THE TREATMENT OF ATOPIC DERMATITIC PATIENTS
Author: Intsar S. Waked, Abdel Hamid N. Deghidi
Purpose: The purpose of this study was to compare Topical versus Continuous Betamethasone Diprobionate Phonophoresis in the Treatment of Atopic Dermatitic Patients Methods: Forty six patients atopic dermatitis were participated in this study and were randomly assigned to one of two groups. Phonophoresis group received continuous 0.05% betamethasone dipropionate phonophoresis, three sessions per week for 4 weeks, and control group received topical betamethasone dipropionate cream daily. Measurements were carried out by ultrasonography and SCORAD score. Results: results revealed that there was a significant difference between both groups as regard to primary outcomes ( SCORAD score) as well as secondary outcomes ( skin thickness measurements). Conclusion: it was concluded that continuous betamethasone diprobionate phonophoresis is a safe and effective modality more than topical cream for the treatment of atopic dermatitis.
Keywords: Phonophoresis, betamethasone dipropionate phonophoresis, SCORAD score, ultrasonography, Atopic dermatitis.
Intsar S. Waked, Abdel Hamid N. Deghidi. TOPICAL VERSUS CONTINUOUS BETAMETHASONE DIPROBIONATE PHONOPHORESIS IN THE TREATMENT OF ATOPIC DERMATITIC PATIENTS International Journal of Current Research and Review. 6(5), March, 01-08
1. Eldy DJ. What’s new in atopic dermatitis? Br. J. Dermatol.2001;(145): 380-384.
2. Staab D, von Rüden U, Kehrt R, Wahn U. The Impact of Childhood Atopic Dermatitis on Quality of Life of the Family. Dermatology and Psychosomatics 2000;1;(4):173-178.
3. Charman, C.R.: Outcome Measures of Disease Severity in Atopic Eczema. Arch. Dermatol. 2000; (136): 763-769,.
4. Kost J, Levy D, Langer R. Ultrasound as a transdermal enhancer. In: Osborne DW, Amann AH, eds. Topical Drug Delivery Formulations: Volume 42. New York, NY: Marcel Dekker inc; 1990: chap 34(603-632).
5. Srbely,S.: Ultrasound in the management of osteoarthritis: part I: a review of the current literature, JCCA J Can Chiropr Assoc. 2008;; 52(1): 30–37.
6. Kuntz AR, Griffiths CM, Rankin JM, Armstrong CW, McLoughlin TL. Cortisol concentrations in human skeletal muscle tissue after phonophoresis with 10% hydrocortisone gel. J Athl Train. 2006;41:321–324.
7. Benson HA, McElnay JC, Harland R. Use of ultrasound to enhance percutaneous absorption of benzydamine. Phys Ther. 1989;69:113–118.
8. Darrow H, Schulthies S, Draper D, Ricard M, Measom GJ. Serum dexamethasone levels after Decadron phonophoresis. J Athl Train. 1999;34: 338–341.
9. Ciccone CD, Leggin BG, Callamaro JJ. Effects of ultrasound and trolamine salicylate phonophoresis on delayed-onset muscle soreness. Phys Ther. 1991;71:666–678.
10. Benson HAE, McElnay JC, Harland R. Phonophoresis of lignocaine and prilocaine from EMLA cream. Int J Pharm. 1988;44:65– 69.
11. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ,Hunter JJ, et al. The UK working party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131:383-396.
12. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
13. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23- 31.
14. Serup J, Keiding J, Fullerton A, Gniadecka M, Gniadecka R. High-frequency ultrasound examination of skin: introduction and guide. In: Serup J, Jemec BE, eds. Handbook of noninvasive methods and the skin. USA: CRC Press, 1995; 239 - 256.
15. Wolkerstorfer A, Strobos MA, Glazenburg EJ, Mulder PG, Oranje AP. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998;39:226-31
16. Byl NN, McKenzie AL, Halliday B, Wong T, O’Connell J. The effects of phonophoresis with corticosteroids: a controlled pilot study. J Orthop Sports Phys Ther. 1993;18:590–600.
17. Bommannan D, Okuyama H, Stauffer P, Guy RH. Sonophoresis, I: the use of highfrequency ultrasound to enhance transdermal drug delivery. Pharmceutical Research. 1992; 9:559-564.
18. Bommannan D, Menon GK, Okuyama H, et al. Sonophoresis, II: examination of the mechanisms(s) of ultrasound-enhanced transdermal drug delivery. Pharmaceutical Research. 1992;9:1043-1047.
19. Nyborg WL. Mechanisms. In: Nyborg WL, Ziskin MC, eds. Biological Effects of Ultrasound. New York, NY: Churchill Livingstone Inc; 1985:23-33.
20. -Cameron MH, Monroe LG. Relative transmission of ultrasound by media customarily used for phonophoresis. Phys Ther.1992 ;72:142–148
21. Tyle P, Agrawala P. Drug delivery by phonophoresis. Pharmaceutical Research. 1989;6: 355-361.
22. -Draper, O.O. and Prentice W.E.: Therapeutic ultrasound. In: Draper, O.O. and Prentice, W.E. (ed): Therapeutic modalities for allied health professional. New York, McGraw- Hill, 1st ed. 263-309, 1998.
23. -Naik, A., Kalia, Y.N, and Guy, R.H.: Transdermal drug delivery: overcoming the skin’s barrier function.PSTT:3(9): 318- 326,2000.
24. Abd El Baky A.M and Waked I.S; Nonsteroidal anti-inflammatory phonophoresis versus topical application in improvement of hand grip strength in psoriatic arthritic patients; Journal of American Science, 2011;7(6); 110-114.
25. Barbara, C.: Phonophoresis versus topical application of ketoprofen: comparison between tissue and plasma level. Phys. Ther. August: 349-356, 2003 .